Bloomberg profiles Novartis' (NVS -0.6%) Afinitor drug, which received FDA approval on Friday...

|About: Novartis AG (NVS)|By:, SA News Editor

Bloomberg profiles Novartis' (NVS -0.6%) Afinitor drug, which received FDA approval on Friday for use in breast cancer. The treatment, which was already authorized for kidney tumors and organ transplant patients, generated sales of $318M in H1; sales could rise to $2.5B by 2016, forecasts Deutsche Bank's Tim Race.